



## Title of Study

**B**ridging Anticoagulation in Patients Who **R**equire Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Sur**G**Ery

## Unique Aspects of Study

The BRIDGE trial is a randomized double-blind, placebo-controlled trial comparing bridging anticoagulation with no bridging anticoagulation in patients with atrial fibrillation or atrial flutter who are receiving warfarin therapy and require temporary interruption of warfarin for an elective surgery or other invasive procedure.

The clinical and statistical coordinating centers are managed by the Duke Clinical Research Institute.

## Patient Population

Patients aged  $\geq 18$  years who are receiving warfarin therapy for at least three months, administered to achieve an INR target range of 2.0–3.0, and who require temporary interruption of warfarin. Eligible patients must have at least one of the following: chronic (permanent or paroxysmal) nonvalvular atrial fibrillation or atrial flutter confirmed by at least one prior electrocardiography recording or pacemaker/ACD interrogation or chronic (permanent or paroxysmal) valvular atrial fibrillation or atrial flutter with evidence of mitral valvular heart disease, and have one of the following major stroke risk factors: aged  $>75$  years; hypertension; diabetes mellitus; CHD or left ventricular dysfunction; or previous ischemic stroke, systemic embolism, or TIA.



**Duke Clinical Research Institute**

From Thought Leadership to Clinical Practice

## Study Objectives

- To compare the efficacy of bridging anticoagulation (therapeutic-dose LMWH) with no bridging anticoagulation (placebo) on the rate of arterial thromboembolic events
- To compare the safety of bridging anticoagulation with no bridging anticoagulation on the rate of major bleeding

## Study Centers and Expected Enrollment

3626 patients at 45 sites in North America

## Study Timelines

Enrollment began in July 2009 and is projected to end in March 2014.

## Sponsor

National Heart, Lung and Blood Institute

## How to Obtain More Information

Call Wanda Parker, RN, MSN, Project Leader, at **(919) 668-8589** or send an email to [parke010@dcri.duke.edu](mailto:parke010@dcri.duke.edu).

